The Inflammatory Response to Ventricular Assist Devices
The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients who are ineligible for transplant has increased steadily in the last decade. In parallel, improvements in VAD design have reduced device size, cost, and device-related complications. These complication...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.02651/full |
| _version_ | 1811233580638011392 |
|---|---|
| author | Gemma Radley Gemma Radley Ina Laura Pieper Ina Laura Pieper Sabrina Ali Farah Bhatti Catherine A. Thornton |
| author_facet | Gemma Radley Gemma Radley Ina Laura Pieper Ina Laura Pieper Sabrina Ali Farah Bhatti Catherine A. Thornton |
| author_sort | Gemma Radley |
| collection | DOAJ |
| description | The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients who are ineligible for transplant has increased steadily in the last decade. In parallel, improvements in VAD design have reduced device size, cost, and device-related complications. These complications include infection and thrombosis which share underpinning contribution from the inflammatory response and remain common risks from VAD implantation. An added and underappreciated difficulty in designing a VAD that supports heart function and aids the repair of damaged myocardium is that different types of HF are accompanied by different inflammatory profiles that can affect the response to the implanted device. Circulating inflammatory markers and changes in leukocyte phenotypes receive much attention as biomarkers for mortality and disease progression. However, they are seldom used to monitor progress during and outcomes from VAD therapy or during the design phase for new devices. Even the partial reversal of heart damage associated with heart failure is a desirable outcome from VAD use. Therefore, improved understanding of the interplay between VADs and the recipient's inflammatory response would potentially increase their uptake, improve patient lives, and fuel research related to other blood-contacting medical devices. Here we provide a review of what is currently known about inflammation in heart failure and how this inflammatory profile is altered in heart failure patients receiving VAD therapy. |
| first_indexed | 2024-04-12T11:22:16Z |
| format | Article |
| id | doaj.art-6f29364893ed425da52ccc37a83a8757 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T11:22:16Z |
| publishDate | 2018-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6f29364893ed425da52ccc37a83a87572022-12-22T03:35:19ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-11-01910.3389/fimmu.2018.02651409218The Inflammatory Response to Ventricular Assist DevicesGemma Radley0Gemma Radley1Ina Laura Pieper2Ina Laura Pieper3Sabrina Ali4Farah Bhatti5Catherine A. Thornton6Swansea University Medical School, Swansea, United KingdomCalon Cardio-Technology Ltd, Institute of Life Science, Swansea, United KingdomSwansea University Medical School, Swansea, United KingdomScandinavian Real Heart AB, Västerås, SwedenCalon Cardio-Technology Ltd, Institute of Life Science, Swansea, United KingdomDepartment of Cardiology, Morriston Hospital, Abertawe Bro Morgannwg University Health Board, Swansea, United KingdomSwansea University Medical School, Swansea, United KingdomThe therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients who are ineligible for transplant has increased steadily in the last decade. In parallel, improvements in VAD design have reduced device size, cost, and device-related complications. These complications include infection and thrombosis which share underpinning contribution from the inflammatory response and remain common risks from VAD implantation. An added and underappreciated difficulty in designing a VAD that supports heart function and aids the repair of damaged myocardium is that different types of HF are accompanied by different inflammatory profiles that can affect the response to the implanted device. Circulating inflammatory markers and changes in leukocyte phenotypes receive much attention as biomarkers for mortality and disease progression. However, they are seldom used to monitor progress during and outcomes from VAD therapy or during the design phase for new devices. Even the partial reversal of heart damage associated with heart failure is a desirable outcome from VAD use. Therefore, improved understanding of the interplay between VADs and the recipient's inflammatory response would potentially increase their uptake, improve patient lives, and fuel research related to other blood-contacting medical devices. Here we provide a review of what is currently known about inflammation in heart failure and how this inflammatory profile is altered in heart failure patients receiving VAD therapy.https://www.frontiersin.org/article/10.3389/fimmu.2018.02651/fullheart failureventricular assist devicesinflammationcytokinesleukocytes |
| spellingShingle | Gemma Radley Gemma Radley Ina Laura Pieper Ina Laura Pieper Sabrina Ali Farah Bhatti Catherine A. Thornton The Inflammatory Response to Ventricular Assist Devices Frontiers in Immunology heart failure ventricular assist devices inflammation cytokines leukocytes |
| title | The Inflammatory Response to Ventricular Assist Devices |
| title_full | The Inflammatory Response to Ventricular Assist Devices |
| title_fullStr | The Inflammatory Response to Ventricular Assist Devices |
| title_full_unstemmed | The Inflammatory Response to Ventricular Assist Devices |
| title_short | The Inflammatory Response to Ventricular Assist Devices |
| title_sort | inflammatory response to ventricular assist devices |
| topic | heart failure ventricular assist devices inflammation cytokines leukocytes |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2018.02651/full |
| work_keys_str_mv | AT gemmaradley theinflammatoryresponsetoventricularassistdevices AT gemmaradley theinflammatoryresponsetoventricularassistdevices AT inalaurapieper theinflammatoryresponsetoventricularassistdevices AT inalaurapieper theinflammatoryresponsetoventricularassistdevices AT sabrinaali theinflammatoryresponsetoventricularassistdevices AT farahbhatti theinflammatoryresponsetoventricularassistdevices AT catherineathornton theinflammatoryresponsetoventricularassistdevices AT gemmaradley inflammatoryresponsetoventricularassistdevices AT gemmaradley inflammatoryresponsetoventricularassistdevices AT inalaurapieper inflammatoryresponsetoventricularassistdevices AT inalaurapieper inflammatoryresponsetoventricularassistdevices AT sabrinaali inflammatoryresponsetoventricularassistdevices AT farahbhatti inflammatoryresponsetoventricularassistdevices AT catherineathornton inflammatoryresponsetoventricularassistdevices |